Acrongenomics Inc., a Swiss life science venture company and Molecular Vision Ltd., a spin-out from the Imperial College London, said they have signed a memorandum of understanding to jointly develop diagnostic devices for diabetes, drug abuse, STDs and cardiovascular diseases.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.